How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about the treatments

Marketing authorisation indications

2.1

Remdesivir (Veklury, Gilead Sciences) is 'indicated for the treatment of coronavirus disease 2019 (COVID-19) in:

  • adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)'

  • adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19'.

2.2

Tixagevimab plus cilgavimab (Evusheld, AstraZeneca) is indicated 'for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19'.

Dosage in the marketing authorisation

Price

2.5

The list price for remdesivir is £340 per 100‑mg vial (excluding VAT; BNF online, accessed October 2022). Costs may vary in different settings because of negotiated procurement discounts.

2.6

The company has a commercial arrangement (simple discount patient access scheme). This makes remdesivir available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.7

The list price of tixagevimab plus cilgavimab is £800 per 300‑mg dose and £1,600 per 600‑mg dose (excluding VAT; prices provided by company). The company has a commercial arrangement, which would have applied if tixagevimab plus cilgavimab had been recommended.